The weekly litigation news digest is live. Subscribe now

IP Verse

Use Of Anti Cd70 Antibody Argx-110 To Treat Acute Myeloid Leukaemia - EP3638696

The patent EP3638696 was granted to Argenx on Jun 26, 2024. The application was originally filed on Jun 18, 2018 under application number EP18732064A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3638696

ARGENX
Application Number
EP18732064A
Filing Date
Jun 18, 2018
Status
Granted And Under Opposition
Feb 2, 2024
Publication Date
Jun 26, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERDec 6, 2024SCRIPTADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONWO2004073656
DESCRIPTIONWO2006044643
DESCRIPTIONWO2006113909
DESCRIPTIONWO2007038637
DESCRIPTIONWO2008074004
DESCRIPTIONWO2012123586
INTERNATIONAL-SEARCH-REPORTWO2012123586
OPPOSITIONWO2006044643
OPPOSITIONWO2012123586
OPPOSITIONWO2013192360

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents